
What Leo Pharma failed to achieve in the UK, the dermatology group has now pulled off in Canada, as the Danish company has won a patent fight against Israeli generics giant Teva Pharmaceutical Industries.
The case pertains to Leo Pharma’s psoriasis ointment Dovobet, marketed in Europe as Daivobet. Teva had attempted to invalidate a patent on this drug.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app